YolTech Therapeutics is at the forefront of gene medicine, leveraging advanced technologies to develop innovative treatments for genetic disorders. Their Genome Editing Platform features a novel toolbox, including the High-Throughput Evolution Platform for Discovery and Optimization of Novel Editors (HEPDONE™), which utilizes AI-powered discovery and metagenomics data. This platform enables iterative high-throughput screening and enzyme engineering, allowing for the identification of highly efficient genome editing tools. The focus is on Base Editing, which allows for precise insertion, deletion, and replacement of DNA without causing double-stranded breaks, thereby minimizing off-target effects and enhancing the safety and efficacy of gene therapies.

In addition to their genome editing capabilities, YolTech has developed a proprietary Lipid Nanoparticle (LNP) Delivery Platform, which is crucial for the effective delivery of therapeutic agents. This platform is supported by an in-house manufacturing process and a proprietary lipid library, ensuring that the delivery systems are optimized for various applications. Together, these technologies position YolTech Therapeutics as a leader in the development of targeted therapies for conditions such as Familial Hypercholesterolemia and Hereditary Transthyretin Amyloidosis, aiming to provide lifelong cures through pioneering gene medicine.

China

YolTech Therapeutics is a biotech focuses on combining mRNA and gene editing technology to develop next-generation mRNA drugs and in vivo gene editing drugs.Our company is a pre-clinical stage gene editing biotech, has built leading genome editing platform and mRNA-LNP library. It possesses strong capability of novel Cas and base editors discovery and exceptional production capacity for LNP drug manufactory, with strong IP protection globally.  It has created a pipeline with 10 genetic medicines focusing on cardiovascular diseases, infectious diseases and rare diseases.

YolTech Therapeutics

Company Details